東陽光(600673.SH):控股子公司境內未上市股份申請全流通獲批
格隆匯6月3日丨東陽光(600673.SH)公佈,公司於2019年11月22日召開公司第十屆董事會第十八次會議,審議通過了《關於申請公司所持有的H股上市公司東陽光藥內資股股份“全流通”的議案》,同意公司將所持有的H股上市公司宜昌東陽光長江藥業股份有限公司(以下簡稱“東陽光藥”)內資股股份全部轉換為境外上市股份並在香港聯交所主板上市流通,並委託東陽光藥向中國證監會提出H股“全流通”的申請及辦理其他股份轉換相關事宜。
經向中國證監會提出H股全流通申請,東陽光藥於2020年6月2日收到了中國證監會下發的正式批覆文件,核准東陽光藥股東廣東東陽光科技控股股份有限公司所持2.26億股境內未上市股份轉為境外上市股份,相關股份完成轉換後可在香港交易所上市,批覆自核準之日起12個月有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.